Autonomix Medical

Autonomix Medical (NASDAQ: AMIX) is a development-stage medical device company headquartered in The Woodlands, Texas, advancing a catheter-based precision neuromodulation platform for sensing and treating disorders of the nervous system. The company's microchip-enabled sensing architecture is designed to detect low-amplitude neural signals from within the vascular system, with an initial focus on treating pancreatic cancer pain and expansion into chronic pain management, hypertension, and cardiovascular indications. On August 4, 2026 the company announced a broad new U.S. patent (No. 12,433,670) supporting nerve sensing, mapping, and targeted therapy, following a July 24, 2026 preclinical study demonstrating renal nerve sensing and neural activity change. The stock surged 434% on the August 4 announcement before giving back 24.6% in after-hours trading.